With unique expertise in aptamer research and development, Base Pair Biotechnologies consistently advances the efficiency of our service, while dramatically reducing costs. Our scientists invented an exclusive multiplex technology that screens up to 30 targets at once. The benefits pass to you:
Welcome to the world of aptamer discovery, where short strands of DNA or RNA are chosen for a higher purpose. It’s our mission to make aptamers more accessible, through collaboration and a business model that understands and adapts to your needs. We even invented a multiplex technology that streamlines the discovery process. Base Pair delivers tangible benefits to your team, with greater efficiency and greater selection:
We don’t believe in charging large up-front discovery costs. Our goal is to get aptamers in your hands. Instead, we establish multiple checkpoints that minimize your risk. It allows you to evaluate your options as the science progresses. Key decisions, such as whether to commercialize your aptamer sequence, can be made when the time is right. Once the results are in, you choose to:
There’s one more very important feature of our progressive ownership model. By minimizing your initial discovery costs, we’re taking a share of the risk. It’s a guarantee that if we don’t think your target is a good candidate for your application, we’ll let you know upfront. We’re a resource as well as a partner for custom aptamer discovery.